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We demonstrate the usefulness of synthetic lethal screening
of a conditionally BCL6-deficient Burkitt lymphoma cell line,
DG75-AB7, with a library of small molecules to determine sur-
vival pathways suppressed by BCL6 and suggest mechanism-
based treatments for lymphoma. Lestaurtinib, a JAK2 inhibitor
and one of the hits from the screen, repressed survival of BCL6-
deficient cells in vitro and reduced growth and proliferation of
xenografts in vivo. BCL6 deficiency inDG75-AB7 induced JAK2
mRNA and protein expression and STAT3 phosphorylation.
Surface IL10RA was elevated by BCL6 deficiency, and blockade
of IL10RA repressed STAT3 phosphorylation. Therefore, we
define an IL10RA/JAK2/STAT3 pathway each component of
which is repressed by BCL6.We also show for the first time that
JAK2 is a direct BCL6 target gene; BCL6 bound to the JAK2
promoter in vitro and was enriched by ChIP-seq. The place of
JAK2 inhibitors in the treatment of diffuse large B-cell lym-
phoma has not been defined; we suggest that JAK2 inhibitors
might be most effective in poor prognosis ABC-DLBCL, which
shows higher levels of IL10RA, JAK2, and STAT3 but lower lev-
els of BCL6 than GC-DLBCL and might be usefully combined
with novel approaches such as inhibition of IL10RA.
There is a need for new treatments for poor-prognosis
activated B-cell-like diffuse large B-cell lymphoma (ABC-
DLBCL),6 which continues to have a cure rate40% with con-
ventional chemotherapy (1).
The majority of ABC-DLBCL, in contrast to germinal center
B-cell-like DLBCL, have low level expression of BCL6 mRNA
and protein (2). JAK/STAT3 signaling is active in ABC-DLBCL
and is enhanced by constitutive activity of the NF-B pathway
(3), which in turn is driven by oncogenic CARD11 mutations
(4), chronic active B-cell receptor signaling (5), and MYD88
mutations (6). However, other factors are also likely to be
important in determining the overall activity of JAK/STAT3
signaling. BCL6 directly represses both STAT3 (7) and NF-B
p105/p50 (8) transcription, and levels of BCL6might, therefore,
be a factor independent of the known oncogenic mutations,
which determines the activity of signaling pathways required by
ABC-DLBCL. In this report we develop a novel B-cell line to
pursue the hypothesis that genes repressed by BCL6 are com-
ponents of survival signaling pathways in lymphomas with low
level expression of this transcription factor.
BCL6 is a zinc finger transcription factor that is highly
expressed in normal germinal center B-cells (9) and is required
for high affinity antibody production (10, 11). It is also consti-
tutively expressed in 40% of cases of the high grade B-cell
lymphoma DLBCL due to either chromosomal translocations,
mutations of a negative regulatory site in the promoter region
(12–14), or abnormalities of post-translational regulation
(15–17).
The N-terminal POZ domain of BCL6 associates with co-re-
pressors NCOR1, BCOR, and SMRT (NCOR2), which in turn
recruit histone deacetylases to accomplish transcriptional
repression. Work largely carried out with human Burkitt lym-
phoma cell lines and mouse B-cell lines showed that BCL6
represses B-cell terminal differentiation through a direct effect
on BLIMP1 (PRDM1) (18–20). Effects on the cell cycle have
been less clearly defined; BCL6 represses cyclin D2 transcrip-
tion (18), but it also suppresses the cyclin-dependent kinase
inhibitor p21 (21) and in primary cells prevents senescence and
induces cyclin D1 (22). Suppression of DNA damage responses
and p53 by BCL6 are believed to be required to allow somatic
hypermutation in normal germinal center B-cells (23, 24). As
mentioned above, STAT3 and NF-B, which are both required
by ABC-DLBCL, are direct targets of BCL6 transcriptional
repression (7, 8).
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We engineered a conditional BCL6-deficient human B-cell
line, DG75-AB7, from an EBV-negative Burkitt lymphoma cell
line proficient for homologous recombination, DG75 (25, 26).
We employed DG75-AB7 in a synthetic lethal screen to deter-
mine compounds inhibiting pathways that are active in BCL6-
deficient cells. Synthetic lethal screening has previously been
employed to find agents that are preferentially effective in the
killing of cell lines bearing a transforming mutation (27) and is
more widely the basis for siRNA and high throughput drug
screens to discover novel therapeutics for cancer (28).
For this study we defined synthetic lethality as reduction of
survival of BCL6-deficient DG75-AB7 cells while relatively
sparing BCL6-replete cells. To carry out the synthetic lethal
screen we employed a library of small molecule inhibitors that
are either in clinical use or are good candidates for clinical use.
Hits from the screen could, therefore, potentially be rapidly
introduced into clinical trials. We demonstrate that IL10RA
and JAK2 are transcriptionally regulated by BCL6 and suggest
(7, 29) that low BCL6 is a determinant of an IL10RA/JAK2/
STAT3 pathway that might be important in survival of some
ABC-DLBCL.
Results
Characterization of a Conditional BCL6-deficient B-cell
Line—BCL6 deficiency reduces survival and causes accumula-
tion in G1.
We produced conditional BCL6-deficient Burkitt lymphoma
cell lines. On the addition of doxycycline BCL6 was effectively
repressed, and proliferation was reduced in three separate
clones (Fig. 1,C andD). Furtherworkwas carried outwith clone
DG75-AB7. When doxycycline was washed out of the culture
medium, the effects on growthwere reversed, suggesting a con-
tinuing requirement for BCL6 (Fig. 1E). After 7 days of culture
doxycycline-treated DG75-AB7 cells had undergone fewer cell
divisions than untreated cells (Fig. 2A) with an accompanying
reduction in survival and an increase in cells in G1 at the
expense of G2M and S phases (Fig. 2B). Overall BCL6-deficient
cells showed reduced proliferation due to G1 growth arrest.
Gene expression profiling was carried out to obtain a com-
prehensive view of BCL6 gene target alterations in DG75-
AB7. 205 genes with a 2-fold up- or down-regulation in at
least one of the samples cultured with doxycycline (16, 48, or
96 h) compared with the basal (doxycycline) sample were
identified. 14/205 genes were not annotated and were hence
excluded from subsequent analysis, leaving 191 genes. Of
these, 162 genes (85%) were up-regulated in response to
BCL6 depletion (Table 1). Validation by RT-polymerase
chain reaction (PCR) was carried out for a subset of these
genes (Fig. 3 and Table 2).
To identify biological pathways altered in response to BCL6
depletion, functional annotation clustering was carried out (32,
33). Cell cycle gene CDKN1B (p27kip2), a previously identified
BCL6 target gene 18, was up-regulated together with other reg-
ulators of cell cycle progression (CDC25A, CDC6, E2F8, and
RB1). Other pathways regulated by BCL6 were B-cell receptor
signaling (SYK, BLNK, PTPRC (CD45), IFITM1 (LEU13 or
CD225), CD72 and PTPN6 (SHP1)) and calcium signaling
(CYSLTR1 (GPCR), ATP2A (SERCA1), ITPR1/ITPR2 (IP3R),
CAMK4 and PTK2B (FAK2, Pyk2)).
Work by others has demonstrated specific functionally
important BCL6 targets (18). Analysis of changes inDG75-AB7
FIGURE1.AconditionalBCL6-deficienthumanB-cell line.A, schemeofdisruptionof the endogenousBCL6 loci ofDG75. A zeocin resistance cassette flanked
by loxP sites was inserted into exon 3 of the BCL6 gene, containing the initiation codon by homologous recombination. After Cre recombinase mediated
removal of the antibiotic resistance gene the process was repeated on the second BCL6 allele. B, Southern demonstrating disruption of the endogenous BCL6
loci and the presence of the inserted BCL6 transgene. GenomicDNAwas digestedwith SphI andprobedwith labeledprobes A andB.Wild-type cells (BCL6/,
lane 1) gavean11.8-kbband.After the first roundof targetingandbefore removal of the zeocin resistance cassette (BCL6/Zeor, lane 2) the11.8 kbbandwas
present with 7.9-kb and 5.1-kb bands from the targeted locus. After removal of the zeocin resistance cassette but before targeting of the second locus
(BCL6/, lane 3) 11.8-kb and 5.1-kb bands were present. After insertion of the BCL6 transgene and targeting of the second locus (BCL6/Zeor  pTRE-
BCL6HA, lane 4) the 11.8-kb band was no longer present, bands of 7.9 kb and 5.1 kb from the disrupted BCL6 loci were present together with a band of 4.1 kb
from the BCL6 transgene. C, growth curves (cumulative doublings) of wild-typeDG75 (WT) and three targeted clones (AB7, CD9, and FA8) in the absence (solid
line) and presence (dotted line) of doxycycline.D, Western showing BCL6 expression inDG75-AB7 in the presence and absence of doxycycline. BCL6 expression
in the DLBCL cell line, SUDHL4 (BCL6 expressing), and HEK293 cells (BCL6 non-expressing) are also shown. E, the effects of doxycycline on proliferation are
reversible.DG75-AB7cellswere cultured in thepresenceor absenceofdoxycyclineorwithdoxycycline for various times (2, 4, or 6days) beforeexchangingwith
culture medium lacking the antibiotic. Proliferation rate (cumulative doublings) were normalized to proliferation of cells cultured without doxycycline.
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to the mRNA expression of these genes showed 30% induc-
tion of expression in 14/19 (73%) on the addition of doxycycline
(Table 3A). In an alternative method to validate the gene
expression changes observed in DG75-AB7, we utilized pub-
lished data, which in another Burkitt lymphoma cell line has
demonstrated a set of genes that bind BCL6 at their genomic
loci (34). 39 of the 44 genes that bound BCL6 by ChIP-quanti-
tative PCR are represented on the gene expression microarrays
we employed, and 18 (46%) of these showed altered mRNA
expression (30% induction or repression) at one ormore time
points after the addition of doxycycline to DG75-AB7 (Table
3B). Although not all genes discovered through ChIP-chip will
be functionally important, our data support a functional role for
several e.g.TNFAIP8, TAP1, SUB1, andCD53, that have not yet
been investigated in detail.
One of the important effects of BCL6 is suppression of DNA
damage responses partly through transcriptional repression of
ATR (23). To show that DG75-AB7 reproduces this aspect of
BCL6 deficiency, DNA damage responses in response to x-irradi-
ationweredetermined.Culture indoxycyclinecaused inductionof
ATR protein in AB7 and significant (Mann-Whitney U test)
reductions in DNA damage in response to x-irradiation (as deter-
mined by H2AX phosphorylation) at 1 Gy (p 0.003), 2 Gy (p
0.007), and 4 Gy (p  0.01) (Fig. 2C). Therefore, DG75-AB7 is a
model system demonstrating gene expression and functional
changes on the addition of doxycycline, in line with known BCL6
effects.
The JAK2 Inhibitor, Lestaurtinib, Reveals a Survival Pathway
in BCL6-deficient Cells—We utilized a drug sensitivity screen
to determine survival pathways in BCL6-deficient DG75-AB7.
The effect of each compound in the library on cell viability was
FIGURE 2. Characterization of DG75-AB7. A, BCL6 deficiency caused a
defect inproliferation.Wild-typeDG75 (WT) andDG75-AB7 (AB7)were loaded
withcarboxy fluorescein succinimidylester (CSFE), and fluorescencewasmea-
sured in the absence (black line) or presence (red line) of doxycycline over the
course of 7 days. Fluorescence histograms are presented. Mean fluorescence
intensity is indicated in the top left corner. B, surviving fraction of DG75-AB7
after culturewithdoxycyclinemeasuredby a luminescence cell viability assay
and cell cycle changes after culture of DG75-AB7 in the absence () or pres-
ence of doxycycline (Dox). Cells were stained with propidium iodide, and cell
cycle analysis was carried out with FlowJo Software. C, Western blot demon-
strating changes in expression of the BCL6 target gene, ATR on culture of
DG75-AB7 with doxycycline (Do). DNA repair capacity in DG75-AB7 was
repressedbyBCL6. Levels ofphosphorylatedH2AXafter x-irradiation ineither
the absence (red bars) or presence (blue bars) of doxycyclineweredetermined
by flowcytometry (n3). H2AX levels specifically inG0/G1 of the cell cycle are
presented. There are significant differences in levels of phosphorylatedH2AX
(Mann-Whitney U test) at 1 Gy (p  0.003), 2 Gy (p  0.007), and 4 Gy (p 
0.01). *, p 0.05, **, p 0.01.
TABLE 1
Genes, whose expression altered<0.5-fold or>2-fold at one or more
time-points after the addition of doxycycline
F-Fold change in expression compared to baseline conditions is presented at 16, 48,
and 96 h. For several genes, e.g. CCL3L1 and TAP1, multiple probes are present on
the Affymetrix chip, and all data are presented in the table. Conditional formatting
is employed such that induced gene expression is colored red, and repressed expres-
sion is colored blue.
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estimatedboth in thepresenceandabsenceofdoxycycline. Ineach
case the effect was quantified as a z-score, with negative z-scores
representing inhibition of cell survival (Fig. 4A). As expected, the
majority of compounds do not show an effect on cell survival, but
comparison of z-score data from DG75-AB7 cell screens in the
presence of doxycycline (BCL6 deficient) or absence of doxycy-
cline (BCL6 replete) allowed identification of compounds that
preferentially reduced survival of BCL6-deficient cells while hav-
ing relatively little effect on BCL6 replete cells (Table 4). Seven
compounds demonstrated z-scores2 at two or more concen-
trations. Of these compounds, paclitaxel and vinorelbine reduced
survival of both BCL6 replete and deficient cells, whereas others,
2-methoxyestradiol, dasatinib, canertinib, lestaurtinib, and sunitinib
appeared to preferentially suppress growth of BCL6 deficient
cells (Fig. 4B). By comparison doxorubicin and flavopiridol
(Fig. 4C) reduced survival without a differential effect on BCL6-
deficient cells, whereas cyclophosphamide and olaparib
showed no effect on either BCL6 replete or deficient cells.
BCL6 Deficiency Induces a Transcriptional Increase in JAK2
Levels—We focused further work on the JAK2 inhibitor, les-
taurtinib, because BCL6 directly represses STAT3 (7), which is
a principle target of phosphorylation by JAK2, and we won-
dered whether BCL6 also repressed JAK2 to cause increased
overall inhibition of JAK2 and STAT3. The addition of doxycy-
cline caused a 4-fold increase in JAK2 mRNA and induction of
JAK2 protein (Fig. 5, A and B). Induction of phosphotyrosine
705-STAT3 accompanied these changes, and lestaurtinib and
twoother JAK2 inhibitors, fedratinib and ruxolitinib, prevented
phosphorylation (Fig. 5C). At the doses employed, ruxolitinib
and to a lesser extent fedratinib, stabilized JAK2 phosphoryla-
tion (in line with their mechanism of action as type I inhibitors
(35)), whereas all three agents repressed STAT3 phosphoryla-
tion. STAT3 transcription factor activity is largely associated
with phosphorylation on tyrosine 705.Westerns blots, utilizing
tyrosine 705- and serine 727-specific anti-phospho-STAT3
showed STAT3 tyrosine 705 after induction of BCL6 defi-
ciency, whereas levels of phosphorylated STAT3 serine 727
remain unchanged (Fig. 5D). Overall, the data demonstrated
preferential reduction of survival of BCL6-deficient DG75-AB7
by lestaurtinib, and consistent with this effect being mediated
by STAT3, JAK2 inhibitors repressed the STAT3 phosphoryla-
tion induced by BCL6 deficiency.
In order to confirm that the reduction in viability observed
with lestaurtinib was mediated through JAK2 we transfected
DG75-AB7 either with siRNA directed against JAK2 or a nega-
tive control siRNA (Fig. 5, E and F). Repression of JAK2 caused
a significant (t test; p 0.008) reduction in cell viability in the
presence of doxycycline.
BCL6 Deficiency Induces IL10RA Expression—Serum IL-10
levels are prognostic in DLBCL (36), and IL10 receptor expres-
sion was increased in ABC-DLBCL as compared with germinal
FIGURE 3. Validation of microarray results by RT-PCR of 14 selected
genes. Primer sequences are presented in Table 2. RT-PCR was carried out
from cDNA produced from DG75-AB7 cultured in the presence (Dox) or
absence (Dox) of doxycycline (1 g/ml) for 96 h. cDNA dilutions of 1, 1:5,
1:25, and 1:125 (left to right as indicated by the black triangles) were prepared
and used as the template for the PCR. Columns to the right show the -fold
induction obtained for each gene from the microarray results and the corre-
sponding inductions calculated from the RT-PCR. Conditional formatting
indicates induced genes (red) and repressed genes (blue) (Microsoft Excel
v14.4.7).
TABLE 2
Primer sequences for RT-PCR presented in Fig. 3
Gene
Primers (5 to 3)
Product sizeForward Reverse
bp
IFI44L tggccaagccgtagtggggt cccgcagcatctgcctcagtg 605
CYSLTR1 tgtgccctgctctctcccct ggtgctgaggcggcacaaga 658
SYK cggctggagagcgaggagga ggcccagtcttgggctgcac 462
PLEK tgaccctgctggggcagaaga acccctgggctgtttcccgt 325
PIK3IP1 tctgggctacgtgctgggca ctcagcccacagggccacct 456
RB1 ccggaggacctgcctctcgt cctcgcctgggtgttcgagg 653
FOXP1 cgggcggcagcaaccactta ggctgcccgggctgaattgt 577
IRF9 agagatcagccgcccagcca gcaacatccatgcggcccct 390
EIF2AK3 ctgcggccgaggtgactgtg ccactgcgaggtccgacagc 562
GPRIN3 gatgggtacaccccgggcct gggaggggagcgcagtcaga 415
B2M agatatgcctgccgtgtg aatccaaatgcggcatct 110
E2F8 gtgcgctcagctgggacctg gctgtcggtgtccacggctc 350
CDC6 gggtgaaggctgcgggttcc ccctttccctggcaggcagc 578
LYAR ggcgctggctgagaggcaat ccccttgctgttccacggcg 669
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FIGURE4.Smallmolecule inhibitor screen forenhanced lossofviability inBCL6-deficientDG75-AB7.A, overviewof the screen. Standardizedvalues (drug
effect z-score), calculated from x (log2 median raw value), (log2 median plate raw values), and  (S.D of differences between log2 raw values in the presence
and absence of doxycycline (Do)) according to the formula z-score ( )/ are plotted for negative controls (DG75-AB7 cells in the absence or presence
of doxycycline but without any of the screening agents) and positive controls (DG75-AB7 cells in the absence or presence of doxycycline and with the potent
kinase inhibitor, staurosporine (10M), to induce apoptosis). For the test samples, standardized values for each agent and at each concentration are shown. B,
effect of agentswith z-scores2 (Table 4) on cell survival determinedbyATP luminescence. Survival of cellswithout doxycycline (solid line) orwith this agent
(dotted line) at four concentrations (1, 10, and 100 nM and 1M) is shown. Lestaurtinib was employed at 0.2, 2, 20, and 200 nM. C, by contrast, doxorubicin and
flavopiridol reduce survival of both BCL6 replete and deficient DG75-AB7 cells, whereas cyclophosphamide and olaparib have no effect on survival.
TABLE 3
Transcriptional regulation of genes after the addition of doxycycline to DG75-AB7
F-Fold induction of mRNA levels at 16, 48, and 96 h after doxycycline treatment are shown. Individual values are color-coded utilizing a conditional formatting tool
(Microsoft Excel v14.4.7) with the scale being from red (the highest value) to white (the lowest value). BCL6 target genes were defined by two alternative approaches. A)
genes determined experimentally to be functional BCL6 targets18, and B) set of genes for which BCL6 binding to the gene locus has been experimentally ascertained by
ChIP-chip (34). In both tables genes are ordered such that the least transcribed (defined by normalized Affymetrix values) is at the top and the most transcribed is at the
bottom. Only CCL3 is present in both tables.
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center (GC)-DLBCL (29). IL10 receptor activation promoted
STAT3 phosphorylation and DLBCL survival (29). We won-
dered whether JAK2/STAT3 phosphorylation required IL10
receptor expression and engagement in DG75-AB7. Induction
of BCL6 deficiency induced IL10RA mRNA expression (Fig.
5G), and flow cytometry showed elevated surface expression of
IL10RA in a population of DG75-AB7 cells (Fig. 5H). It is not
clear why IL10RA expression was not induced in all cells. Exog-
enous IL10 induced STAT3 tyrosine phosphorylation, which is
repressed by a blocking anti-IL10 antibody (Fig. 5I), demon-
strating that IL10RA engagement is required for STAT3 phos-
phorylation. Collectively, our data implicates BCL6 in sup-
pressing an IL10RA/JAK2/STAT3 pathway.
Lestaurtinib Combined with Induced BCL6 Deficiency Is
Effective in a Mouse Xenograft Model—To evaluate in vivo effi-
cacy of lestaurtinib in combination with BCL6 deficiency, we
utilized SCID-beige mouse xenografts. Animals were flank-in-
jected with DG75-AB7 and divided into four groups (n  8).
Although there were no obvious histological differences
between tumors in untreated animals and those that had
received either doxycycline in the drinkingwater or lestaurtinib
by intraperitoneal injection (Fig. 6), those tumors from animals
that received both agents unexpectedly showedmassive central
necrosis. As compared with untreated animals, mice that
received either doxycycline or lestaurtinib alone showed
reduced growth, and the combination of agents produced fur-
ther repression (Fig. 6C). Immunohistochemical assessment of
proliferation demonstrated that the combination of doxycy-
cline and lestaurtinib increased the fraction of non-proliferat-
ing Ki-67 negative cells (Fig. 6D). Therefore, BCL6 deficiency
was sufficient to markedly repress tumor growth without alter-
ing the fraction of Ki-67-expressing cells, but the combination
of BCL6 deficiency and lestaurtinib significantly (Mann-Whit-
neyU test;p 0.007) increasednumbers ofKi-67-negative cells
and was associated with tumor necrosis.
JAK2 Is a Direct Target of BCL6 Transcriptional Repression—
Inspection of the JAK2 promoter region identified a possible
BCL6 binding site at1185 bp from the transcription start site
(Fig. 7A). To demonstrate BCL6 binding to this sequence in
vitro, we utilized gel shift assays employing lysates from the
BCL6 expressing Ramos Burkitt lymphoma cell line and labeled
JAK2 promoter BCL6 binding sequence (J2B6BS) oligonucleo-
tide. A protein-DNA complex was effectively competed by a
consensus BCL6 binding sequence (FB20) (7), and an anti-
BCL6 antibody caused disappearance of the shifted band (Fig.
7B), therefore, identifying the complex as containing BCL6.
FB20 oligonucleotidewas able to competemore effectively than
J2B6BS for binding to BCL6, suggesting a relatively weak inter-
action at the JAK2 promoter. To show in vivo BCL6 binding at
the JAK2 promoter, we analyzed publicly available ChIP-seq
databases (37). Statistically significant peaks (Table 5) of BCL6
binding corresponded with BCOR co-repressor binding with-
out evidence of SMRT or NCOR binding (Fig. 7, C and D),
supporting both a direct effect of BCL6 and association with
BCOR at the JAK2 locus. To demonstrate BCL6 binding at the
JAK2 locus inDG75-AB7, a single siteChIP assaywas employed
and showed 30-fold more binding in the absence of doxycy-
cline (Fig. 7E). Next, reporter assays were carried out in
TABLE 4
Small molecule inhibitor screen
Compounds at concentrations from 1, 10, 100, and 1000 nM were administered
to DG75-AB7 in the presence or absence of doxycycline, and the surviving
fraction was measured. Drug-effect z-scores were calculated. Standardized
value (drug effect z-score) is calculated from x (log2 median raw value without
doxycyclinelog2 median raw value with doxycycline), (log2 median plate raw
values), and  (S.D. of differences between log2 raw values in the presence and
absence of doxycycline) according to the formula z-score (x )/. z-scores
of 2 or less at two or more concentrations were obtained for 2-methoxye-
straduiol, dasatinib, canertinib, lestaurtinib, paclitaxel, and sunitinib (indicated
by the brown bar to right of table). z-scores of 2 or less at one concentration-
only were obtained for a further group of compounds (blue bar to right of table),
and compounds for which no significant z-scores were obtained are indicated by
the orange bar to right of table. Individual z-scores were color-coded utilizing a
conditional formatting tool (Microsoft Excel v14.4.7) with red indicating low,
white indicating mid-range, and blue indicating high scores.
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FIGURE 5. BCL6 deficiency leads to both transcriptional increase in JAK2 and STAT3 phosphorylation. A, mRNA levels of JAK2 determined over 4 days in the
presenceofdoxycyclinerelativetoJAK2 levels inDG75-AB7culturedwithoutdoxycycline.B, JAK2protein levelsdeterminedbyWesternblot inDG75-AB7afterculture
for4dayswithdoxycycline (Dox).C, JAK2 inhibitors suppressSTAT3phosphorylation.Westernblots showingexpressionofphosphorylatedJAK2andphosphorylated
STAT3 inDG75-AB7 in theabsence (Dox) andpresence (Dox)ofdoxycycline (Do) andafter treatmentwith lestaurtinib (Le; 200nM), fedratinib (2M), andruxolitinib
(200 nM). D, specific phosphotyrosine-STAT3 expression. Western blots showing expression of phosphorylated STAT3-tyrosine 705 (pY-STAT3), phosphorylated
STAT3-serine 727 (pS-STAT3), total STAT3, and BCL6 in the presence or absence of doxycycline (Dox) or lestaurtinib (Le) as indicated. E, JAK2 siRNA knockdown.
DG75-AB7weremock-transfected (lanes 1 and 4) and transfectedwith a JAK2 siRNA (lanes 2 and 5) or a scrambled (scr) negative control siRNA (lanes 3 and 6) in the
absence (lanes 1–3) or presence (lanes 4–6) of doxycycline). Cell lysates were harvested 48 h after transfection and 24 h after the addition of doxycycline. F, relative
viability compared with mock-transfected cells without doxycycline. Column numbers are as in E above. G, induction of IL10RA mRNA after repression of BCL6 in
DG75-AB7. JAK2 siRNA significantly reduces (t test, p 0.008) viability in the presence of doxycycline. **, p 0.01.H, histograms showing IL10RA expression by flow
cytometry onDG75-AB7 in the presence (Dox) or absence (Dox) of doxycycline. Light gray indicates isotype control, and dark gray indicates anti-IL10RA. I, effects
of IL-10 and blocking anti-IL-10 antibody on STAT3 phosphorylation. DG75-AB7 was cultured in the presence of doxycycline and IL10 (10 ng/ml) in the presence of
either a blocking anti-IL10RA antibody (5g/ml) or an isotype control antibody.Western blottingwas carried out for pY-STAT3.
FIGURE 6. JAK2 inhibition synergizes with BCL6 deficiency to cause tumor necrosis in vivo. A, hematoxylin- and eosin-stained sections of representative
tumors excised from the flanks of animals receivingneither doxycycline (Dox) nor lestaurtinib (Do-Le) either agent alone (Do-LeorDoLe) or both agents
together (DoLe). Tumors were removed after 12 days of treatment. B, histology and immunohistochemistry of tumors frommice treated as indicatedwith
doxycycline (Dox) or lestaurtinib (Le). The top row of photomicrographs shows hematoxylin- and eosin-stained sections. Themiddle row shows sections stained
with anti-BCL6, and thebottom rowdemonstrates stainingwith anti-Ki-67. Insets showhigherpower views.C, increase in tumor volumecalculatedasdescribed
under “Experimental Procedures.” Data represent the mean volumesS.E. (n 8). D, numbers of Ki-67-positive and -negative cells were counted in six high
power fields of sections from four mice from each experimental group. Mean percentage (S.E.) of Ki-67 negative cells is shown.
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HEK293 cells to demonstrate the functional importance of the
binding site (Fig. 7F). Transcription was repressed from the
wild-type promoter, in response to a transfected BCL6 expres-
sion vector, and there was relief of repression on mutation of
the BCL6 binding site. This result was confirmed in DG75-AB7
(Fig. 7G) Therefore, there is a functional BCL6 binding site in
the JAK2 proximal promoter region, and BCL6 binds to this
region in vivo, supporting the direct transcriptional repression
of JAK2 by BCL6.
Expression of JAK2andBCL6mRNAAre Inversely Correlated
in Human DLBCL—To obtain data on relative JAK2 and BCL6
mRNA expression in primary human lymphoma, we analyzed a
publicly available gene expression database (38). JAK2mRNA is
expressed significantly more highly in ABC-DLBCL compared
with GC-DLBCL (Fig. 8). This adds to previously published
data that both STAT3 and IL10RA are found in significantly
greater amounts in ABC-DLBCL (7, 29).
Discussion
Burkitt lymphoma cell lines have been useful in determining
mechanisms of action and gene targets of BCL6 (18, 39–41).
FIGURE7.JAK2isadirectBCL6targetgene.A, BCL6bindingsites in theJAK2promoterwithpositions relative to the transcriptionstart site.B, invitrobindingofBCL6
to the JAK2 BCL6 binding sequence. Gel shift assay were carried out with lysates fromDG75-AB7 cells in the absence of doxycycline and labeled JAK2 BCL6 binding
sequenceoligonucleotide (J2B6BS) (50 fmol). Theadditionof a super-shiftinganti-BCL6antibody (aBCL6) causeddisappearanceof the specific bandand formationof
the specific BCL6-DNA complexwas effectively competedby unlabeled FB20 (a consensus BCL6binding site 7) and also by J2B6BS. Nonspecific (ns) bands thatwere
neither super-shifted nor competed by unlabeled oligonucleotide were observed. C, ChIP-seq demonstrating in vivo BCL6 binding at the JAK2 locus of the OCI-Ly1
diffuse largeB-cell lymphomacell lineemployingdata from37.Thegraybar indicates thepeakofBCL6andBCORbindingat theproximalpromoter region.D, zoom-in
viewof theChIP-seqdata todemonstrate theBCL6binding site (B6BS).E, single siteChIPassay. ChIPwascarriedoutwithanti-BCL6andanti-actin antibodies followed
by real-timePCR for theBCL6binding site at the JAK2 locus anda site at theCD20 locus,whichdoesnotbindBCL6. -Foldenrichment is comparedbetweenanti-BCL6
andanti-actinantibodies.DOX, doxycycline.F, luciferasereporterassays.HEK293cellsweretransfectedwith0,50,or200ngofamammalianexpressionvectorbearing
full-lengthBCL6cDNA (as indicatedby theblack triangles) and luciferasevectorsbearingeither 2 kbof theproximal JAK2promoter (WT) or this regionwithmutations
of the BCL6 binding site 1 (Mut) or a vector bearing a luciferase gene without any inserted promoter sequence (Ctrl). Each experiment (n 3) was carried out in
triplicate. For WT, Mut, and Ctrl results are normalized to the condition without transfected BCL6 expression vector. There are significant differences (paired t test)
betweenmutated andwild-type JAK2 promoter sequences for both 50 ng (p 0.015) and 200 ng (p 0.03) of transfected BCL6 expression plasmid. *, p 0.05.G,
luciferase reporter assay. DG75-AB7 cells were transfectedwith luciferase reporter constructs as before. Cells cultured in the presence of doxycycline showed signif-
icantly enhanced (paired t test; p 0.02) reporter activity. *, p 0.05. (n 3). Irr. Ab., irrelevant antibody.
TABLE 5
Statistical summary of ChIP enrichment data at the JAK2 locus from
GEO data, GSE29282 (37)
The statistical test used compares each sample to the reference using a one-tailed
binomial test. A false discovery rate of 0.001 was also applied. Partek Genomics
Suite software version 6.6 (Copyright 2014; Partek Inc., St. Louis, MO) was
employed to do the analysis. Absolute signal (read number) and computed signifi-
cance of enrichment (p value) are presented.
Antibody
BCL6 BCOR
Scaled -fold change (ChIP vs INPUT) 33.23 10.8
p value (CHIP vs INPUT) 1045 1045
Total reads in region (ChIP) 248 1455
Total reads in region (INPUT) 8 127
Interval length 346 1173
Chromosome 9 9
Start 4,975,124 4,974,600
Stop 4,975,470 4,975,773
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BothBCL6 (42, 43) and the geneswhose transcription it directly
inhibits (3, 7, 8) are potential targets for therapy in DLBCL. To
produce amodel system for the systematic evaluation of BCL6-
and BCL6-regulated pathways for therapy, we produced a con-
ditional BCL6-deficient Burkitt lymphoma cell line that repro-
duces the functional effect of BCL6 on DNA damage responses
(23) andmany of the gene expression changes known to be due
to BCL6. This novel cell line has significant advantages over
previousmethodologies (18) becauseminimumperturbation is
required to suppress BCL6.
BCL6 deficiency suppressed proliferation of DG75-AB7 and
reduced the surviving fraction of cells, but similar towork using
a peptide inhibitor to abrogate BCL6 function in a Burkitt lym-
phoma cell line (44),50%of cells remain viable.Wewondered
whether specific pathways, normally repressed by BCL6,
became active under these conditions to maintain survival.
Others have shown that genes normally repressed by BCL6 can
contribute to survival specifically in ABC-DLBCL (7). To reveal
pathways required for survival of BCL6-deficient DG75-AB7,
whichmight prove to be important in ABC-DLBCL, we carried
out a synthetic lethal screen of DG75-AB7 against a library of
small molecule inhibitors, many of which are in clinical use or
are candidates for clinical use, and sought a reduction in the
surviving fraction of cells, which was greater than that pro-
duced by BCL6 deficiency alone.
Several agents from the library screenwere found to enhance
the effects of BCL6 deficiency. We chose to focus on lestaur-
tinib, a JAK2 inhibitor. JAK2 is activated in DLBCL (36) but has
not previously been reported to be a direct target of BCL6 tran-
scriptional repression.Weproduced several lines of evidence to
support a direct effect of BCL6 on JAK2; 1) JAK2 mRNA levels
increased in response to BCL6 deficiency, 2) BCL6 bound to the
JAK2 promoter in vivo and in vitro, and 3) a BCL6 binding site
in the JAK2 promoter region was required for BCL6-mediated
repression in luciferase reporter assays.
We demonstrated that STAT3, a major target of phosphor-
ylation by JAK2, was induced and phosphorylated in BCL6-
deficient DG75-AB7. STAT3 mRNA expression is directly
repressed by BCL67, and BCL6 also represses IL-6 production
in macrophages to inhibit STAT3 signaling (45), but a role for
BCL6 in regulating JAK2 has not been previously demon-
strated. JAK-STAT signaling has been investigated in DLBCL;
this pathway can be activated by IL-10 (36) and by diverse
genetic mechanisms such as aberrant MYD88 signaling (6) or
inactivatingmutation of SOCS1 (46). Overall theremay be con-
stitutive STAT3 signaling in 50% of DLBCL (3, 7), but acti-
vating mutations of JAK2 appear to be very rare, and mecha-
nisms for JAK2 activation in DLBCL other than activating
mutations have been suggested (47). Here we show that JAK2,
like STAT3, is a direct BCL6 target gene in a Burkitt lymphoma
cell line, and this raises the possibility that BCL6 contributes to
the overall regulation of JAK2-STAT3 signaling.
It was surprising that JAK2 was not only increased in
amounts on induction of BCL6 deficiency in DG75-AB7 but
was also phosphorylated. We noted that IL10RA mRNA
increased on induction of BCL6 deficiency in DG75-AB7,
showing that it is directly or indirectly regulated by BCL6
(Table 1), and we wondered whether engagement of this recep-
tor could mediate JAK2 phosphorylation. Experiments with
IL10RA blocking antibodies supported the notion that BCL6
deficiency activated an IL10RA/JAK2/STAT3 pathway.
Our data suggested that an IL10RA/JAK2/STAT3 pathway is
repressed by BCL6. IL10RA, JAK2, and STAT3 have been
shown separately to be components of pathways that are spe-
cifically active in ABC-DLBCL. Both STAT3 (7) and IL10RA
(29) have been suggested as targets for therapy in ABC-DLBCL,
and ABC-DLBCL cell lines are more sensitive to JAK2 inhibi-
tion thanGC-DLBCL cell lines (3). In addition, high serum IL10
levels carry a poor prognosis in DLBCL (36). Through our work
we were able to link this disparate data to show that there is a
role for BCL6 in the regulation of all these genes. Therefore,
BCL6 appears to repress a survival pathway in ABC-DLBCL,
and systematic future studies of BCL6 target genesmight reveal
other important survival mechanisms in ABC-DLBCL.
There has been interest in employing JAK2 inhibitors in
DLBCL (48, 49), but the place of these agents has not been
defined. We suggest that they might be useful adjuncts to con-
ventional treatment in cases of ABC-DLBCL expressing rela-
tively low levels of BCL6 and that BCL6 mRNA expression
might be a component of a biomarker panel to predict patient
populations that will benefit from these drugs.
Experimental Procedures
Construction of DG75-AB7—Both BCL6 alleles of the paren-
tal EBV negative Burkitt lymphoma cell line, DG75-354 (gift of
Dr. Berthold Henglein), which contains a tetracycline transac-
tivator, were disrupted by homologous recombination, and a
tetracycline repressible BCL6 cDNA was inserted to produce
DG75-AB7. Exon 3, which contains the translation start site of
BCL6, was disrupted (Fig. 1, A and B). The targeting construct
contains a zeocin (zeo) resistance cassette that is flanked by
loxP sites followed by a downstream SphI site with flanking
arms of homology targeting it to the BCL6 gene. The construct
contains a unique KpnI restriction site facilitating linearization
before gene targeting. After transformation of the parent
DG75-354 cells i.e.DG75 containing a tetracycline transactiva-
tor construct, with this construct and subsequent selection in
zeocin, targeted integration events were detected by PCR
screening and confirmedby Southern blotting.Gene disruption
was targeted to the 11763-bp genomic SphI fragment, which
flanks exon 1b and finishes in exon 6. The arms of homology
FIGURE8.BCL6, JAK2, STAT3, and IL10RAexpression levels basedonpre-
viously published gene expression profiling of cases of diffuse large
B-cell lymphoma (50). The signal values for BCL6 (probe 24429), STAT3
(probe 31469), JAK2 (probe 17330), and IL10RA (probe 34420) were retrieved
for 71 ABC-DLBCL and 110 germinal center (GC) B-cell-like DLBCL samples.
The data had been previously log2-transformed and median-centered for
each gene across the entire sample set. The p values are calculated by non-
parametric Mann-Whitney (U test) to compare the values between the two
DLBCL subgroups. Bars indicate the group medians.
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were subcloned as a smaller fragment derived from this initial
big construct. This 10-kb region was amplified from genomic
DNA. This 9992-bp KpnI/SacII fragment was ligated into
pBluescriptKS (Stratagene), resulting in vector p10kb-homo-
logy. The 8918-bpApaI/EagI fragment of p10kb-homology was
then subcloned from p10kb-homology into pBluescript KS
generating p8.9kb-homology. For disruption of theBCL6 allele,
a zeocin cassette was inserted into the SbfI site of p8.9kb-ho-
mology (end of exon 3). This 1245-bp zeocin cassette (including
its promoter) was amplified from pCMV/Zeo utilizing primers
adding loxP sites to both ends of the zeocin cassette and an SphI
restriction site to its 3	 end. This SbfI-digested product was
cloned into the SbfI site of p8.9kb-homology to generate the
final targeting construct pTarg-BCL6. The orientation of the
zeocin cassette was verified by restriction enzyme digestion,
and the region surrounding the 5	 loxP site was sequenced.
After targeting of the first BCL6 allele, cells were transiently
transfected with Cre-recombinase (pMC-Cre kindly supplied
byH.Gu,University ofKo¨ln), which excised the region between
the loxP sites. The premature stop codon generated by targeted
BCL6 gene disruption is likely to result in the mRNA being
degraded by nonsense-mediated decay. The potential transla-
tion of the message would result in a 55-amino acid truncated
protein, whichwas expected to be nonfunctional and quickly be
degraded. Once the zeocin cassette and resistance was lost, the
same targeting construct was used to knock-out the second
allele.
Gene Expression Analysis—Gene expression changes due to
the absence of BCL6 were measured by Affymetrix (Santa
Clara, CA)microarrays. Total RNAwas extracted usingRNeasy
minipreps (Qiagen, Hilden, Germany), and 100 ng of total RNA
was processed with the GeneChip Eukaryotic Whole Tran-
script Sense Target Labeling Assay kit (Affymetrix). Briefly
double-stranded cDNA was synthesized from total RNA using
random hexamers tagged with a T7 promoter sequence and
transcribed in vitro by T7 RNA polymerase to produce anti-
sense cRNA. This was subsequently purified and used as tem-
plate for a further round of cDNA synthesis. After RNA hydro-
lysis, treatment of sense cDNAwith uracil DNAglycosylase and
apurinic/apyrimidinic endonuclease 1 (APE1) fragments the
DNA strand. cDNA fragments are labeled by terminal deoxy-
nucleotidyltransferase (TdT) with biotin and hybridized to the
array (Human GeneChip 1.0 ST Array, Affymetrix), which was
subsequently scanned.
The Quality of Microarray Data Were Evaluated by Box
Plot and Scatter Plot Analysis—Real time RT-PCR-JAK2 and
IL10RA mRNA levels were determined by real time PCR per-
formed using an Applied Biosystems 7500 Real-Time PCR
machine (Applied Biosystems, Foster City, CA) and Taqman
Universal PCR Master Mix. JAK2 primers were: forward (5	-
CAGGCAACAGGAACAAGATG) and reverse (5	-CCATTC-
CCATGCAGAGTCTT); IL10RA primers were forward (5	-
CAGGAACTGACGGATTGGGAA) and reverse (5	-GCTTC-
AAACCACACAGACGG).
SmallMolecule Inhibitor Screen—DG75-AB7was seeded at a
density of 5 104 cells/ml in a 384-well plate in a volume of 50
l/well on day 0 and continuously cultured in the presence or
absence of doxycycline (1 g/ml) as well as a library of small
molecule inhibitors (Table 4) for 4 days at which point cell
survival was estimated. The small molecule library encom-
passed conventional chemotherapy and targeted therapy
agents at four different concentrations. In total, six replica
experiments were performed with the data from the replicas
combined in the final analysis. Staurosporine (10 M) was used
as a positive control for the induction of apoptosis. Cell viability
was estimated at the end of the experiment using the CellTiter-
Glo (Promega, Southampton, UK) luminescence assay. 20l of
CellTiter-Glo reagent was added to each well, the plate con-
tents were mixed for 10 min at room temperature, and the
luminescence was measured. Each culture condition was repli-
cated six times. Raw luminescence values were log2-trans-
formed and then z-score-standardized according to the log2
median effect and the variance of effects, which was estimated
by calculation of the median absolute deviation.
Cell Culture, Growth, Cell Cycle, Flow Cytometry, and DNA
Double-strand Break Analysis—Parental DG75 cells and its
derivatives were cultured in RPMI media (Life Technologies)
supplemented with 10% fetal calf serum (Lonza, Basel, Switzer-
land) and penicillin (10,000 units/ml) (Lonza) and streptomy-
cin (10,000 g/ml) (Lonza) and grown at 37 °C and 5% CO2.
Where indicated, doxycycline (1 g/ml) (D9891; Sigma) in
DMSO (D2650; Sigma) was added to the culture medium. For
cell culture DG75-AB7 was cultured with doxycycline for 4
days, and inhibitors ruxolitinib and fedratinib (Selleck Chemi-
cals, Houston, TX) and lestaurtinib (Tocris Bioscience, Bristol,
UK) were added for 24 h.
Cells excluding trypan blue were counted, and cultures were
split every 2 days so that concentrations did not exceed or fall
below the preferred cell density of between 1 and 9 105 cells/
ml. The doubling time (Td) between time point 1 (t1) and time
point 2 (t2) (in h)was calculated by inserting cell concentrations
at time point t1 (c1) and time point t2 (c2) into the formula Td
(t2 t1) (ln2/ln(c2/c1)).
For cell cycle analysis, 106 cells were collected by centrifuga-
tion, washed once in PBS, and resuspended in PBS (300 l).
Ice-cold ethanol (700 l) was added, and the fixed cells were
collected by centrifugation, washed once in PBS, and resus-
pended in 500 l of PBS containing RNase A (0.2 mg/ml) (Qia-
gen) and digested at 37 °C for 1 h. Propidium iodide was added
to a final concentration of 40 g/ml, and cells were analyzed by
flow cytometry.
Expression of IL10RA was determined by flow cytometry
(FACSCanto, BD Biosciences) utilizing anti-IL10RA antibody
(R&D Systems, Minneapolis, MN; MAB2742) in the presence
of human Fc block (BD Biosciences; 564219). Detection was
with secondary anti-mouse IgG-FITC (Jackson Immuno-
Research, West Grove, PA; 315-096-003). A blocking anti-
IL10RA antibody (Novus Biologicals, Oxford, UK; NBP1–
42534) was employed at 5 g/ml to demonstrate functional
effects. IL10 (R&D Systems) was employed at 10 ng/ml.
DG75-AB7 cells were cultured for 4 days in the presence or
absence of doxycycline after which DNA double-strand breaks
were induced by irradiation at a dose rate of 1Gy/min at 250 kV
constant potential and half-value layer of 1.5 mm copper (Pan-
tak Industrial x-raymachine (Pantak Inc., East Haven, CT)). 2 h
after irradiation DNA double-strand breaks were identified
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using fluorescent detection of the phosphorylated form of
H2AX (H2AX). 5 105 cells were fixed using ice-cold ethanol
for at least 24 h at 4 °C and then permeabilizedwith 0.1%Triton
X-100 on ice for 10 min with 0.2 mg/ml RNase (Sigma; R6513);
cells were then incubated at 37 °C for 1 h, blocked with 4% FCS,
and stained with a 1:500 dilution of anti-H2AX (Ser-139)
(clone JBW301; Millipore 05–636) for 2 h on ice and then with
a 1:200 dilution of secondary antibody (AlexaFluor488 goat
anti-mouse IgG; Invitrogen A21121) with rotation at room
temperature (in the dark) for 1 h. After washing, cells were
stained with propidium iodide (0.5 g/ml) and analyzed on a
FACSCanto II (BD Biosciences) and characterized for cell cycle
stage using FlowJo Software v7.6.4 (Treestar Inc., Ashland,OR).
The mean fluorescent intensity of H2AX was determined for
cells within G1 of the cell cycle.
Chromatin Immunoprecipitation—Binding of BCL6 to the
JAK2 locus was analyzed by ChIP (carried out as described
Papadopoulou et al. (30)) with an anti-BCL6 antibody (N3;
Santa Cruz Biotechnology, Santa Cruz, CA), and the results
were analyzed by real-time PCR. BCL6 binding to the CD20
locus was used as a control (31). JAK2 primers were forward
(5	-ggttcattctcatccttcagat-3	) and reverse (5	-agtagaaagtga-
ggagggggtgt-3	).
Luciferase Reporter Assays—A 2.0-kb region upstream of the
JAK2 transcription start site was cloned from DG75-AB7
genomic DNA. The gene was amplified by PCR using MyFi
polymerase (Bioline, London, UK) and the primers 5	-taaggtac-
cccttgtccaccttg-3	 (forward, with a KpnI site) and 5	-cct-
gctagcttcgaactcagc-3	 (reverse, with a NheI site). The site was
also cloned in the reverse orientation using the primers 5	-
taagctagcccttgtccaccttg-3	 (forward, with a NheI site) and
5	-cctggtaccttcgaactcagc-3	 (reverse, with a KpnI site). The
amplified product was digested with KpnI andNheI and cloned
into the empty pGL4 Luciferase Reporter Vector, pGL4.10
(Promega, Fitchburg, WI). Site-directed mutagenesis was per-
formed using the QuikChange II XL kit (Agilent, Santa Clara,
CA) to create amutated binding site, GGCCGAGAA.Allmuta-
tions were confirmed by sequence verification. HEK-293 cells
were transiently transfected with Turbofect transfection re-
agent (Thermo Scientific, Waltham, MA) following the man-
ufacturer’s instructions. Cells were seeded in 96-well white-
bottomed plates 24 h before transfection. The cells were then
co-transfected with BCL6-FLAG expression construct (50 or
100 ng) and/or empty pGL4.10 reporter vector to 200 ng total
DNA.After 8 h the cells were then co-transfectedwith 100 ng of
the various reporter constructs and 100 ng of pGL4.73 Renilla
Luciferase construct. All transfections were performed in trip-
licate and luciferase activities were measured using the Dual-
Glo LuciferaseAssay System (Promega) 24 h after reporter con-
struct transfection. All luminescence readingswere normalized
to Renilla luciferase control readings. Reporter assays (without
co-transfection of BCL6 expression construct) were similarly
carried out in DG75-AB7 in the presence and absence of
doxycycline.
Western Blotting Analysis—DG75-AB7 cells were harvested
and lysed in radioimmune precipitation assay buffer (150 mM
sodium chloride, 1.0% Nonidet P-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease
inhibitors (Sigma). Protein was separated by 7.5% SDS-PAGE
(Bio-Rad). Gels were blotted to polyvinylidene difluoridemem-
branes and probed with antibody. Anti-ATR (Abcam, Cam-
bridge, UK; ab4471), anti-BLIMP1 (Cell Signaling Technology,
Beverly, MA; #9115), anti-MYC (Cell Signaling Technology;
#9402), anti-JAK2 (Cell Signaling Technology; #3230), anti-
phospho-STAT3-Tyr-705 (Cell Signaling Technology; #9145),
and anti-phospho-STAT3-Ser727 (Cell Signaling Technology;
#9134) were all employed at 1:1000. Secondary anti-mouse IgG
or anti-rabbit IgG were employed at 1:2000. Anti-STAT3 (Cell
Signaling Technology; #9132) was employed at 1:2000, and sec-
ondary anti-rabbit IgG was employed at 1:5000.
Electromobility Shift Assays (EMSA)—EMSAs were carried
out utilizing a LightShift Chemiluminescent EMSA kit
(Thermo Scientific, Waltham, MA; 20148). EMSAs were per-
formed using the LightShift Chemiluminescent EMSA kit
(Thermo Scientific). Binding reactions containing 20 g of
nuclear protein lysate were preincubated for 15 min at room
temperature in EMSA binding buffer (10 mM Tris, 50 mM KCl,
1 mM DTT, 10 mM MgCl2, 10 M ZnCl2, 100 g/ml BSA, 4%
glycerol, 2 g of Poly (dIdC)) before the addition of a biotin-
labeled probe and a subsequent 20-min incubation at room
temperature. Complexes were separated on 5% Tris borate-
EDTA polyacrylamide gels before electrophoretic transfer to
nylon membranes and detection as per the manufacturer’s
instructions. For specific-competition analysis a 200-fold
excess of unlabeled probe was added before the preincubation.
For supershift analysis, 2g of antibody was incubated with the
binding reaction for 20 min after the preincubation and before
the addition of the labeled probe. The test probe was designed
to the putative BCL6 binding site in the JAK2 promoter region
(5	-ACGATTTCCTAGAATAAGTG-3	). The canonical BCL6
probe FB20 was used as a positive control (5	-GAAA-
ATTCCTAGAAAGCATA-3	).
siRNA Knockdown—DG75-AB7 were transfected with
siRNA directed against JAK2 (Life Technologies, 4392420) or a
negative control siRNA (#4390843) using siPORT NeoFX (Life
Technologies) after which they were cultured for 24 h. Doxycy-
cline was then added to half the cells, which were then cultured
for a further 24 h and harvested, and CellTiter-Glo lumines-
cence (Promega) was determined.
In Vivo Adoptive Transfer—18–22-Week-old SCID-Beige
mice (Charles River, Burlington, MA) were inoculated subcu-
taneously in the flank with DG75-AB7 (1 107 cells in 100 l)
premixed with equivolume amounts of Matrigel HC (Sigma,
E1270) under general anesthesia. Tumors were left to establish
for 7 days, and then the mice were assigned to one of four
groups (n  8). Group 1 received no treatment and regular
drinking water and provided a baseline for tumor development
andmorphology. Group 2 received doxycycline (Sigma D9891)
in the drinking water at 1 mg/ml. Group 3 received regular
drinking water and once daily subcutaneous injections of les-
taurtinib (10 mg/kg), and Group 4 received doxycycline in the
drinking water (as before) in combination with once daily sub-
cutaneous injections of lestaurtinib (10 mg/kg).
Lestaurtinib (LC Laboratories, Woburn, MA) was resus-
pended to a final concentration of 5 mg/ml in 40% PEG100
(Sigma 76293), 10% povidone C30 (Sigma P2472), and 2% ben-
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zyl alcohol (Sigma 402834). Lestaurtinib was administered for 5
days of 7 (Monday to Friday) only. Due to some skin sensitivity
the injection sites were rotated between the scruff and flanks.
All groups received water ad libitum, and the mean water
intake per mouse was calculated (6.5 ml/mouse/day) corre-
sponding to a mean dose of doxycycline 300 mg/kg/mouse/
day. No differences in fluid intake were noted between the
groups. Animals were typically caged in single sex pairs, in con-
ditions appropriate for immune-deficient mice (irradiated diet
and bedding). After tumor initiation, body condition and tumor
volumes were recorded daily, and water intake was monitored
weekly. Tumor growth was monitored by measurement of the
length (L) and the width (W) with Vernier calipers. Tumor vol-
ume was calculated by the formula volumeW2 0.5 liter.
When tumor volumes in two or more of the control mice
exceeded 10mm in size (inmore than 2 dimensions), the exper-
imentwas terminated (under veterinary advice). Bodymass and
tumor mass measurements were made, and tissues were col-
lected from all mice from all groups. All animal procedures
were carried out in the Central Research Facility, University of
Leicester, under the UK Home Office License Number PPL60/
4399 and following National Cancer Research Institute guide-
lines with regard to maximum permissible tumor size.
Spleen samples were formalin-fixed (10% neutral-buffered
formalin), dehydrated (70% ethanol), and impregnated with
wax, and 4-m sections were cut (following standard proto-
cols). Staining with hematoxylin and the eosin was performed
using Shandon Varistain staining machine according to the
manufacturer’s instructions.
The sections were dewaxed in xylene and rehydrated in alco-
hol. Antigen retrieval was carried out using a high temperature
unmasking technique with diaminobenzidine chromagen solu-
tion (DAKO) high pH target retrieval solution in the micro-
wave. Sections were quenched with peroxidase block, and
sections were incubated with the monoclonal anti-BCL6 or
anti-Ki-67 antibodies (DAKO) (1/10 dilution in TBS) for 45
min and rinsed with TBS/Tween buffer followed by incubation
with the HRP-labeled polymer for 45 min and counterstaining
with hematoxylin.
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